Axoltis Pharma
Yann GODFRIN, Ph.D., is a highly experienced professional in the life sciences sector, currently serving as a Board Member at Stromacare SAS and the Chief Executive Officer of both Axoltis Pharma and GODFRIN Life-Sciences. Yann has a history of co-founding and leading several companies, including ERYTECH Pharma, where responsibilities included being Chief Scientific Officer, and HEMOXymed Europe, where focus was on clinical phase IIa logistics. An educational background includes degrees in Biomedical Engineering and Life and Health Sciences, culminating in a Ph.D., with additional expertise acquired through a Master's in Drug Clinical Development. Contributions to the field include innovations in product development and regulatory processes, demonstrating a commitment to advancing healthcare through scientific and business acumen.
This person is not in any teams
Axoltis Pharma
Axoltis pharma is a biopharmaceutical company dedicated to develop a first-in-class disease-modifying drug to treat patients with neurodegenerative or traumatic neurological disorders with high unmet medical needs. Our innovative approach: combining Preventative, Neuroprotective, Regenerative & Remodeling properties in a single drug, as the key to cure complex neurological disorders. Our products are first-in-class multifunctional peptides with high potential in many CNS disorders.